Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Resonance Health Ltd ( (AU:RHT) ) is now available.
Resonance Health Ltd announced significant leadership changes with Dr. Martin Blake retiring as Chair and Non-Executive Director, to be succeeded by Mr. Aaron Brinkworth following the AGM on November 13, 2025. Mr. Andrew Harrison, the current CEO, will also take on the role of Managing Director, reflecting the company’s strategic focus on governance and growth. These changes are expected to strengthen Resonance Health’s position in the healthcare technology industry, as the company continues to expand its portfolio and global reach.
More about Resonance Health Ltd
Resonance Health is an Australian healthcare technology and services company known for its non-invasive medical imaging solutions. The company provides services globally to clinicians for disease management and to pharmaceutical companies for clinical trials. It has achieved regulatory clearances for its Software-as-Medical Devices (SaMDs) in the USA, Europe, UK, and Australia, and holds ISO 13485 certification. Its products include FerriScan®, FerriSmart®, HepaFatScan®, and HepaFatSmart®, which are used for assessing liver conditions.
Average Trading Volume: 412,444
Technical Sentiment Signal: Sell
Current Market Cap: A$18.83M
Find detailed analytics on RHT stock on TipRanks’ Stock Analysis page.